Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study - Wikidata - awgldk - TriplyDB

Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study

Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study

http://www.wikidata.org/entity/Q28729087

about

Cardiovascular safety of methylphenidate among children and young people with attention-deficit/hyperactivity disorder (ADHD): nationwide self controlled case series study Canadian guidelines on pharmacotherapy for disruptive and aggressive behaviour in children and adolescents with attention-deficit hyperactivity disorder, oppositional defiant disorder, or conduct disorder Tamsulosin treatment for benign prostatic hyperplasia and risk of severe hypotension in men aged 40-85 years in the United States: risk window analyses using between and within patient methodology An inventory of European data sources for the long-term safety evaluation of methylphenidate Attention-Deficit Hyperactivity Disorder and Long-QT Syndrome: Risky Business Long-QT Syndrome and Therapy for Attention Deficit/Hyperactivity Disorder.Methylphenidate off-label use and safety.Antidepressant use and risk of coronary heart disease: meta-analysis of observational studies.ADHD & Pharmacotherapy: Past, Present and Future: A Review of the Changing Landscape of Drug Therapy for Attention Deficit Hyperactivity Disorder Comorbidities in ADHD children treated with methylphenidate: a database study An exploratory study of the combined effects of orally administered methylphenidate and delta-9-tetrahydrocannabinol (THC) on cardiovascular function, subjective effects, and performance in healthy adults Risk of Suicidal Events With Atomoxetine Compared to Stimulant Treatment: A Cohort Study.Stimulant therapy in children with attention-deficit/hyperactivity disorder and concomitant long QT syndrome: A safe combination?Use of drugs for ADHD among adults-a multinational study among 15.8 million adults in the Nordic countries.Attention-deficit hyperactivity disorder medication use: factors involved in prescribing, safety aspects and outcomes.Cardiovascular safety of stimulants in children: findings from recent population-based cohort studies.Cardiovascular effects of methylphenidate, amphetamines and atomoxetine in the treatment of attention-deficit hyperactivity disorder: an update.Managing the risks of ADHD treatments.Assessment of potential cardiovascular risks of methylphenidate in comparison with sibutramine: do we need a SCOUT (trial)?Evaluation of acute cardiovascular effects of immediate-release methylphenidate in children and adolescents with attention-deficit hyperactivity disorder Stimulants Use in Attention Deficit Hyperactivity Disorder (ADHD) Kids - Triumph or Tribulation?The cardiovascular safety of methylphenidate Internal validation of Medicaid Analytic eXtract (MAX) data capture for comprehensive managed care plan enrollees from 2007 to 2010.Sensorineural hearing loss associated with neomycin eardrops and nonintact tympanic membranes.Safety of ibuprofen in infants younger than six months: A retrospective cohort study.

P2860

Q24658644-4A930901-B700-41E7-A1B4-A01CF20F713B Q28260681-1F754976-688F-4F98-BCEB-9015C848E23E Q28301391-EF8EBDF8-9C63-476C-A76C-D39935EADD25 Q30603225-6172C59D-39DD-43E1-8E10-4611AED5F6A7 Q33165891-5CBB60D0-5D67-4691-980B-E736AF180F17 Q33165982-A559CFFB-C6C6-46BD-B783-F6D30CB0672C Q34172165-E936AF3A-D26F-420C-B7CB-CB004995EE32 Q34410894-F10DB13B-81C1-46CB-9DCA-47F37B86706C Q34493964-4C96A696-7E0C-43D5-9045-A95313012EB9 Q34538107-FA9FC133-66C3-497C-8678-5B63B23EDFC3 Q34603303-D34626A3-45D4-4859-8F41-2BEFE69DC482 Q36838216-CB79FB4C-DFD8-4298-B283-3D30A5F58009 Q37374833-5493281A-920A-464B-879A-E8834514507B Q37416392-D8AB5CDC-EAB2-4C2D-9D8A-4C9673A85207 Q37722786-278D84D1-A3AB-471F-9A59-957C13FF61AE Q38126419-1E1F45CA-AA8D-44D6-824C-045D0B5C2530 Q38240014-24B62EF9-6955-4084-83C2-CF7A2C0E6100 Q38241131-37788CB0-622E-4FC5-A3E8-D36582FCD18A Q38242438-4C345E00-8BF7-4FCD-817A-30AA67BBA520 Q40654140-B6AC3878-7F16-42FB-85C4-1DC294F8695B Q41974269-72AF5403-3AA7-4903-B329-CB94F800C5C1 Q42748697-9F7E41C5-D83B-47B6-B42A-AF93CA81A3B5 Q47360597-777DCF17-F2FE-46BC-AD73-B7627A907718 Q50357886-8C4B2B0D-AC48-48F5-8DA8-1C5CBDD2825D Q55449426-A7D86EFD-5060-4625-BA1E-C99FC396F8E0

P2860

Cardiovascular safety of central nervous system stimulants in children and adolescents: population based cohort study

http://www.wikidata.org/entity/Q28729087

description

2012 nî lūn-bûn

@nan

2012 թուականի Յուլիսին հրատարակուած գիտական յօդուած

@hyw

2012 թվականի հուլիսին հրատարակված գիտական հոդված

@hy

2012年の論文

@ja

2012年論文

@yue

2012年論文

@zh-hant

2012年論文

@zh-hk

2012年論文

@zh-mo

2012年論文

@zh-tw

2012年论文

@wuu

name

Cardiovascular safety of centr ...... population based cohort study

@ast

Cardiovascular safety of centr ...... population based cohort study

@en

Cardiovascular safety of centr ...... population based cohort study

@nl

type

label

Cardiovascular safety of centr ...... population based cohort study

@ast

Cardiovascular safety of centr ...... population based cohort study

@en

Cardiovascular safety of centr ...... population based cohort study

@nl

prefLabel

Cardiovascular safety of centr ...... population based cohort study

@ast

Cardiovascular safety of centr ...... population based cohort study

@en

Cardiovascular safety of centr ...... population based cohort study

@nl

P1433

Q28729087-62824D91-A476-4347-8BAC-15D2F12EE2A6

P1476

Q28729087-B9B72187-2146-4C91-A66C-E04D39EA7164

P2093

Q28729087-12B02E7D-1A8A-4D78-9585-8AE6901CB28C

Q28729087-278C5E67-B2CC-42D2-B29A-A711CADBAC49

Q28729087-35547FB5-4EF9-49DA-97DD-A904104F8F2C

Q28729087-70942628-EEBF-4C87-A41D-22CBCD6B079D

Q28729087-8115B20C-0A6E-441B-8138-694278757FC1

Q28729087-BB54E6C0-F109-4C8F-B59A-E3AA596D1990

P2860

Q28729087-06827E16-86F1-4FF4-BA57-697348AE6161

Q28729087-0728E278-D4B7-4976-8D3D-DA9F1D2EFE9D

Q28729087-1B765284-ECAD-4C34-A95F-0C8A050D2AD7

Q28729087-1D3DDCE6-810A-407E-B2A8-31F29F10D2FB

Q28729087-23793A6D-2E9E-4C19-970E-448EB822D912

Q28729087-2A514556-C951-43A1-996D-AFF2CE5FCA69

Q28729087-2F19F531-2542-4E72-9DFF-96A921BFF957

Q28729087-384F5F18-0976-428F-87C6-244AFB585B1D

Q28729087-3EB1A7A0-6859-471E-8039-B437CA90ED05

Q28729087-47DB188F-CBD0-4693-82C1-5081A7CAAE64

P304

Q28729087-9F3ABC59-6178-448A-A3F0-BE90CAEF4CA4

P31

Q28729087-3DAAF40E-1CB9-43BC-B8B4-115ECCED8356

P3181

Q28729087-086E167F-59AA-4F7A-BB11-8BB971DBD708

P356

Q28729087-AA0B043E-BAF5-4643-870B-CF3E2D590449

P407

Q28729087-612164A0-87A3-49BB-8961-E8000DFD6839

P433

Q28729087-937198F0-69AC-4300-8268-EF2CBA928600

P478

Q28729087-34D5F232-2C23-4FBE-8E63-204E29EEF835

P50

Q28729087-1679569F-B1E1-40D6-9BF6-CD0E30CEB9C4

Q28729087-420C9CD0-D86F-4873-A939-1200C303AB8E

Q28729087-932A45D4-C86A-44B0-90D9-366F9390A730

P577

Q28729087-577DC411-75B3-47C8-AF61-E9BA20A22474

P5875

Q28729087-6D0B6EB8-30DF-4C7A-8E13-3981A335C2F7

P698

Q28729087-EED80CDE-819E-4CC6-B695-4CC111D5679C

P921

Q28729087-72E160D9-A500-4356-B4BF-E27BF8B34B60

Q28729087-C72A13F1-074D-4C96-907F-4DD4C6C42124

P932

Q28729087-0EBB7683-4F69-45AD-8C93-733E11BBF9B8

P3181

P356

P1433

P1476

Cardiovascular safety of centr ...... population based cohort study

@en

P2093

Arwa Saidi

http://www.w3.org/2001/XMLSchema#string

Jonathan J Shuster

http://www.w3.org/2001/XMLSchema#string

Julie Zito

http://www.w3.org/2001/XMLSchema#string

Mark Olfson

http://www.w3.org/2001/XMLSchema#string

Stephan Linden

http://www.w3.org/2001/XMLSchema#string

Stephen Crystal

http://www.w3.org/2001/XMLSchema#string

P2860

ADHD drugs and serious cardiovascular events in children and young adults

ADHD drugs and cardiovascular risk

A method of estimating comparative rates from clinical data; applications to cancer of the lung, breast, and cervix.

Stimulants and cardiovascular events in youth with attention-deficit/hyperactivity disorder

Cardiovascular events and death in children exposed and unexposed to ADHD agents

Tachycardia-induced cardiomyopathy.

European guidelines on managing adverse effects of medication for ADHD.

A computer case definition for sudden cardiac death.

Atypical antipsychotic drugs and the risk of sudden cardiac death.

Tachycardia-induced cardiomyopathy: a review of animal models and clinical studies.

P304

e4627

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P3181

1165579

http://www.w3.org/2001/XMLSchema#string

P356

10.1136/BMJ.E4627

http://www.w3.org/2001/XMLSchema#string

P407

P433

jul18 1

http://www.w3.org/2001/XMLSchema#string

P478

345

http://www.w3.org/2001/XMLSchema#string

P50

Almut G. Winterstein

Paul S. Kubilis

P577

2012-07-18T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P5875

229325703

http://www.w3.org/2001/XMLSchema#string

P698

22809800

http://www.w3.org/2001/XMLSchema#string

P921

Aparato circulatorio

P932

3399772

http://www.w3.org/2001/XMLSchema#string